We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals

172 hedge funds and large institutions have $1.34B invested in Mirum Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 69 increasing their positions, 53 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 53

5.88% more ownership

Funds ownership: 108.37%114.24% (+5.9%)

7% less call options, than puts

Call options by funds: $1.79M | Put options by funds: $1.93M

8% less funds holding

Funds holding: 187172 (-15)

10% less capital invested

Capital invested by funds: $1.49B → $1.34B (-$155M)

36% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 36

43% less funds holding in top 10

Funds holding in top 10: 74 (-3)

Holders
172
Holders Change
-15
Holders Change %
-8.02%
% of All Funds
2.48%
Holding in Top 10
4
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-42.86%
% of All Funds
0.06%
New
23
Increased
69
Reduced
53
Closed
36
Calls
$1.79M
Puts
$1.93M
Net Calls
-$141K
Net Calls Change
-$873K
Name Holding Trade Value Shares
Change
Change in
Stake
CUAMC
126
China Universal Asset Management Company
China
$225K +$97.8K +3,558 +66%
ASRS
127
Arizona State Retirement System
Arizona
$209K -$2.36K -86 -1%
Principal Financial Group
128
Principal Financial Group
Iowa
$209K +$2.86K +104 +1%
GLA
129
Great Lakes Advisors
Illinois
$209K -$32.8K -1,192 -13%
JRP
130
Jasper Ridge Partners
California
$206K -$484K -17,619 -68%
VOYA Investment Management
131
VOYA Investment Management
Georgia
$206K -$55.4K -2,015 -20%
Wells Fargo
132
Wells Fargo
California
$198K +$23.9K +869 +12%
CSS
133
Cubist Systematic Strategies
Connecticut
$181K -$1.3M -47,150 -87%
LSA
134
Leonteq Securities AG
Switzerland
$126K
TRCT
135
Tower Research Capital (TRC)
New York
$84.2K -$24.2K -882 -21%
SI
136
Sofinnova Investments
California
$75.7K -$9.61M -349,385 -99%
Simplex Trading
137
Simplex Trading
Illinois
$72K -$86.3K -3,140 -52%
PD
138
Point72 (DIFC)
United Arab Emirates
$68.4K +$74.8K +2,721 New
AIP
139
Ameritas Investment Partners
Nebraska
$66.2K
BBHC
140
Brown Brothers Harriman & Co
New York
$62.8K +$35.9K +1,305 +109%
Royal Bank of Canada
141
Royal Bank of Canada
Ontario, Canada
$58K -$153K -5,551 -71%
WIA
142
Wetzel Investment Advisors
Indiana
$56.6K +$27.5K +1,000 +71%
EC
143
EntryPoint Capital
New York
$41.9K -$2.72K -99 -6%
MLICM
144
Metropolitan Life Insurance Company (MetLife)
New York
$36.3K
Pacer Advisors
145
Pacer Advisors
Pennsylvania
$31.1K +$34.1K +1,240 New
AB
146
Amalgamated Bank
New York
$21K -$73.1K -2,660 -76%
Osaic Holdings
147
Osaic Holdings
Arizona
$18.8K -$4.92K -179 -19%
AF
148
Allworth Financial
California
$15.8K
PA
149
Parallel Advisors
California
$10.4K
EC
150
Elequin Capital
New York
$8.92K +$7.2K +262 +282%

MIRM Hedge Fund Activity: Q1 2024 in Review

172 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q1 2024, worth a combined $1.34B — down 10% from $1.49B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of MIRM and 23 opened new positions — a net loss of 13 holders — while 53 trimmed existing stakes and 69 added.

The largest buyer was State Street, adding an estimated $29.9M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $15.8M sold.

  • 172 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q1 2024, down from 187 in Q4 2023.
  • Funds reported $1.34B of Mirum Pharmaceuticals stock for Q1 2024, down 10% quarter-over-quarter.
  • 23 funds opened new Mirum Pharmaceuticals positions in Q1 2024 and 36 closed out, a net change of -13 holders.
  • The largest Mirum Pharmaceuticals buyer in Q1 2024 was State Street, an estimated $29.9M added.
  • The largest Mirum Pharmaceuticals seller in Q1 2024 was Perceptive Advisors, an estimated $15.8M sold.

Based on aggregated 13F filings for Q1 2024.